Ozette, a spin out of Fred Hutch and AI2, is a technology-driven life sciences startup engineering a transformative leap in cell discovery and annotation of the human immune system.

Ozette aims to build an immune monitoring platform powered by technologies developed at Fred Hutchinson.

Ozette was founded in 2020 by Raphael Gottardo, Greg Finak and Evan Greene. The company is headquartered in Seattle, Washington.

Ozette’s intelligent computational analysis technology unlocks the full potential of single-cell data. The AI-powered analysis, rooted in research pioneered at the Fred Hutchinson Cancer Center and incubated at the AI2, reveals high-resolution, reliable insights an order of magnitude faster than the gold standard manual analysis.

Ozette’s technology was able to automatically resolve several hundred distinct immune cell populations, and find a correlation between drug response and a set of rare cell populations that had never been characterized previously.

Ozette has continued to work with the Cancer Immunotherapy Trials Network and other partners to look at over $100M of clinical trial data to date.

Ozette is backed by Madrona Venture Group, Allen Institute for Artificial Intelligence (AI2), M12, Cercano Management, Alexandria Venture Investments, OCV Partners, Duke University, and others. The company raised $26M in Series A round on Jul 28, 2022. This brings Ozette's total funding to $32M to date.